By Arthur Allen, KFF Health News

While the FDA is streamlining regulation of copycat versions of the expensive drugs that millions take for arthritis, cancer, and other diseases, the U.S. patent office is making it harder for the cheaper medicines to get on the market, industry officials say.

Related Articles

Latino US citizens racially profiled by federal immigration agents in Chicago: ‘I felt like a piece of trash’

MAHA idealism meets political reality as RFK Jr. attempts to wrangle a growing movement

Trump and Mamdani meet Friday in the Oval Office. They’ve cast each other as adversaries for months

Supreme Court meets to weigh Trump’s birthright citizenship restrictions, blocked by lower courts

Leaders arrive for a first African G20 summit overshadowed by a rift between the host

See Full Page